The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared ... person's appetite and regulate their blood sugar.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment ... and regulate their blood sugar.

Semaglutide and tirzepatide are medications used to manage type 2 diabetes and aid in weight loss, both belonging to a class of drugs that mimic certain hormones (GLP-1) involved in blood sugar ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Measuring blood sugar has joined sleep and exercise tracking as wellness trends, with some longevity experts claiming that ...